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Particulate delivery system can be used for improving the 
efficacy of protein and peptide drug. In addition to a polymer-
based particulate delivery system, self-nanoemulsifying drug 
delivery system (SNEDDS), a lipid-based delivery system, is 
currently developed for either less water-soluble or soluble drugs. 
This study aims to design SNEDDS for oral insulin administration 
and its in vitro-in vivo study. The SNEDDS template was designed 
using D-optimal mixture design and was analyzed using software 
Design Expert 7.1.5. The obtained optimum template was loaded 
with insulin and evaluated for its transmittance percentage, 
emulsification time, particle size, zeta potential, stability, the 
amount of insulin in vitro diffused across rat intestine, and insulin 
serum concentration after oral administration. The study results 
revealed that the optimum template of SNEDDS formula consisted 
of 10% (w/w) Miglyol 812N, 65% (w/w) Tween 80, and 25% (w/w) 
propylene glycol. These optimum template then was loaded with 
insulin and characterized. SNEDDS insulin has particle size of 
12.0±1.7 nm, zeta potential of +0.16mV, transmittance of >90%, 
and emulsification time of < 60 seconds. The stability study 
showed that SNEDDS insulin was stable from both precipitation 
and phase separation. The amount of insulin transported from 
SNEDDS formula in vitro was 32.45±2.03% and non-SNEDDS 
formula was 10.44±5.04%. In vivo study of SNEDDS insulin 
produced a significantly increased Cmax, AUC, and F value than 
insulin non SNEDDS (p < 0.05). In brief, SNEDDS formulation in 
this study is a promising approach to increase the effectiveness of 
oral insulin. Insulin is better given orally in SNEDDS formulation 
than in non SNEDDS formulation. 
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INTRODUCTION  
Oral insulin has not been commercially 
available due to the low bioavailability of insulin 
in the gastrointestinal tract (Sadrzadeh et al., 
2007). The enzymatic degradation in the 
gastrointestinal tract and low permeability of 
intestinal membrane result in the low 
bioavailability of per-oral insulin (Almaeda and 
Souto, 2007). 
The approach for oral protein 
formulation is the use of specific excipients such 
as absorption enhancers, enzyme inhibitors, 
mucoadhesive polymers, and other formulations 
enabling protein protection against extreme 
environment in the gastrointestinal (Park et al., 
2011) like encapsulation of various delivery 
system including nanoparticles (Sonaje et al., 
2009; Nair et al., 2017; Kunasekaran and 
Krishnamoorthy, 2015), microemulsion 
(Sharma et al., 2010), self-nanoemulsifying drug 
delivery system (SNEDDS) (Ma et al., 2006; Li et 
al., 2012; Zhang et al., 2012; Sakloetsakun et al., 
2013; Rao et al., 2008; Rachmawati et al., 2010), 
liposome (Wu et al., 2011), and mixed with an 
aqueous extract obtained from Desmodium 
Gangeticum roots (Kurian et al., 2010). Among 
those preparations, SNEDDS is potential to be 
developed as a protein delivery system. 
SNEDDS is a homogenous complex system 
which consists of oil, surfactant, co-surfactant, 
and co-solvent (Patel et al., 2013). The system is 
also named as emulsion pre-concentrate. By 
light agitation in aqueous media leads to the 
formation of translucent emulsion (Mishra et al., 
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2014). In some studies, SNEDDS is proven to 
be superior rather than the lipid solution due to 
the surfactant availability in its formulation; it is 
homogenous, the drug absorption is more 
consistent, it protects drugs against 
gastrointestinal environment, the bioavailability 
gets increased, and the efficiency of absorption 
becomes higher (Kaur and Harikumar, 2013). 
SNEDDS has been applied to deliver 
hydrophobic drugs such as coenzyme Q10 
(Khattab et al., 2016), halofantrine (Michaelsen et 
al., 2013), simvastatin (Thomas et al., 2013), 
vitamin E-rutin (Khan et al., 2015), and 
cyclosporine A (Jain et al., 2015). Some studies 
reveal that SNEDDS is also used for protein and 
peptide drug such as BSA (Rachmawati et al., 
2002; Winarti et al., 2016a; Winarti et al., 2016b), 
β-lactamase (Rao et al., 2008), Insulin (Ma et al., 
2006; Li et al., 2012; Zhang et al., 2012, 
Sakloetsakun et al., 2013). 
SNEDDS insulin prepared by previous 
researchers (Li et al., 2012; Zhang et al., 2012) 
using phospholipid to produce insulin 
phospholipid complex. The resulted insulin-
phospholipid complex improved the insulin 
solubility in oil. Other reseracher prepared 
SNEDDS for mucus permeating by initially 
processing the insulin through hidrophobic ion 
pair of insulin/dimyristoyl phosphatidylglycerol 
method to improve the insulin solubility in the 
system and prevent from burst release 
(Karamanidou et al., 2015). This formulation of 
SNEDDS insulin resulted in higher in vitro and 
in vivo permeability.  
In this study, insulin was dissolved in 
glycerol and incorporated in optimum 
SNEDDS template optimized using D-optimal 
mixture design. The optimum SNEDDS 
template loaded insulin was characterized              
and evaluated for in vitro diffussion study and in 
vivo study. The study using rat was approved by 
the Ethics Commission of Integrated Reserach 
and Testing Laboratory, Universitas Gadjah 
Mada no. 00077/04/LPPT/X/2016.  
The approach applied in this research is 
said to be able to succeed the generation of 
effective insulin delivery system. In addition, this 
study suggests interesting possibilities for other 
proteins formulated by SNEDDS. Studies using 
insulin as active ingredient that apply this 
approach have not been established. Therefore, 
this study aims to develop optimum SNEDDS 
template for potential oral insulin delivery.  
 
MATERIAL AND METHODS 
This study used Bovine Insulin from 
Beijing Top Science Biotechnology Co., Ltd., 
Miglyol 812N from CREMER OLEO GmbH & 
Co.KG, Tween 80, Span 20, Span 85 from Sigma 
Aldrich, Chremophor EL 40 was a gift from 
Shanghai Terppon China, propylene glycol from 
Bratachem Indonesia, glycerol from Merck, 
Bradford reagen kit from BioRad, Female Wistar 
rats obtained from Pharmacology and Pharmacy 
Clinic Laboratory of Pharmacy Faculty 
University of Gadjah Mada, and ELISA Bovine 
Insulin Kit from ALPCO USA.  
 
Compatibility study of oils-surfactants-
co-surfactant mixture 
Various oil components consist of Miglyol 
812N, Span 85, and oleic acid, surfactants 
(Tween 80, Tween 20, and Cremophor EL 40), 
and co-surfactants (Span 20, and propylene 
glycol) used for SNEDDS component. The 
compatibility of oil: surfactants: co-surfactants 
(1:1:1, 1:2:1, 1:3:1, 1:4:1, 1:5:1, 1:6:1, 1:7:1, 1:8:1, 
2:1:1, 2:2:1, 2:3:1, 2:4:1, 2:5:1, 2:6:1, 2:7:1, 2:8:1, 
3:1:1, 3:2:1, 3:3:1, 3:4:1, 3:5:1, 3:6:1, 3:7:1, 3:8:1) 
was visually observed for three days. The 
mixtures of the components with the largest 
miscibility area and with the highest emulsion 
transparency produced at a short emulsification 
time were used to construct the ternary phase 
diagram and to optimize the composition of 
SNEDDS templates.  
 
Construction of pseudoternary phase 
diagram 
Based on the compatibility study, the 
mixtures of the components that fulfilled the 
evaluation criteria were used to construct the 
pseudoternary phase diagram.   
 
Optimization of SNEDDS template with 
D-optimal 
The optimization using D-optimal 
mixture design was performed on three 
independent variables which are oil (Myglyol 81) 
10-25%, surfactant (Tween 80) 50-80%, and co-
surfactant (propylene glycol) 10-25%, and it was 
also on two dependent variables which are % 
transmittance (Y1) and emulsification time (Y2).  
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Optimum formula verification 
The optimum formula verification was 
done to determine the suitability of the predicted 
value with the value of the observation (actual 
value).  
 
Preparation of insulin SNEDDS 
Insulin was dissolved in glycerin and was 
stirred in the mixture of surfactant (Tween 80), 
co-surfactant (propylene glycol) and Myglyol 
812N. Each gram of SNEDDS template was 
added with 100μL of glycerin containing insulin. 
 
Determination of emulsion droplet size 
and zeta potential 
SNEDDS Insulin was added with 
distilled water (1:1000) in a test tube. The 
particle size was measured and the polydispersity 
index (PDI) of the formulated nanoemulsion 
was analyzed using DelsaTM Nano Beckman 
Coulter. 
 
Evaluation of emulsification time 
SNEDDS insulin of 250.0µL was quickly 
dripped into a baker glass using 250.0mL 
distilled water, simulated gastric fluid PH 1.2 and 
phosphate buffer pH 6.8 at 37±0.5ºC. The 
medium was stirred at a speed of 100rpm 
(Weerapol et al., 2014). The time to form 




SNEDDS insulin of 100µL was added to 
a vial containing 10mL and 100mL double 
distilled water, Simulated Gastric Fluids pH 1.2, 
and phosphate buffer pH 6.8 at the room 
temperature, stirred for a minute and measured 
for its transmittance using SpectroVis at λ 650 
nm (Reddy and Sowjanya, 2015). 
 
Procedure of in vitro difussion study 
(Ussing Chamber) 
The diffusion study was conducted using 
Ussing Chamber and intestine of male Wistar 
rats put on a chip chamber. SNEDDS insulin 
(1mL) was dispersed in AIF (Artificial Intestinal 
Fluids) at pH 6.8 and put into the mucosal 
compartment. The non-SNEDDS insulin was 
used as the comparator. Phosphate buffer saline 
pH 7.4 was added into serosal compartment. 
The Ussing chamber was set on the water bath 
at 37±0.5ºC. The oxygen was distributed at the 
speed of ±100 bubbles per minute to keep the 
membrane function. Sampling technique was 
performed by taking 1 mL solution of the serosal 
at the 0th, 15th, 30th, 45th , 60th, 90th, 120th, 180th, 
240th, and 300th minute. To keep the sinking 
condition, the solution was changed to 1 mL of 
serosal media. The sample obtained was 
centrifuged at a speed of 3.000rpm for 5min to 
eliminate intestinal debris. The content 
detection was performed with visible 
spectrophotometer through validated micro 
Bradford Assay. This method was carried out by 
reacted 160µL sample solution with 40µL 
Bradford Reagent, then allowed to stand for at 
least 5min, and no more than 1h. Absorbance 
was measured at maximum wavelengths against 
blanks. 
 
In vivo pharmacokinetic study 
Experimental animal 
The experimental animal used in the in 
vivo test was treated based on the approved 
procedure by the Ethics Commission of LPPT 
UGM no. 00077/04/LPPT/X/2016. The 
animals used are healthy 1.5–2-month-old 
female Wistar rats (150-250g). The rats were 
kept in light cage for 12h and in dark cage for 12 
h, and were given standard diet and sufficient 
water access (ad libitum). 
 
Induction of diabetes 
The induction of diabetes in rats were 
performed through the injection of 
Intraperitoneal Streptozotocin (48mg/kg) in 
10mM citrate buffer (pH 4.5) of rats fasted for 
14h with water access (ad libitum). The rats for 
the following test were selected based on the 
glucose level >250mg/dL after five days of 
streptozotocin induction. 
 
Treatment of experimental animals 
The study for blood insulin profile was 
conducted by randomly dividing 28 rats into 
seven groups; each group consists of 4 rats. The 
experimental groups of the study are:  Grup I 
was given 5.0mL/200g blank SNEDDS (oral); 
Grup II was given 43.39IU/KgBW SNEDDS 
Insulin (1mL oral); Grup III was given 
108.47IU/KgBW SNEDDS insulin (2.5mL 
oral); Grup IV was given 216.94IU/KgBW 
SNEDDS insulin (5mL oral), Grup V was given 
5.0 mL/200gr PBS pH 7.4 (oral); Grup VI was 
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The blood sample (0.5mL) was obtained 
from the eye orbital sinus at the 0th, 15th, 30th, 
45th, 60th, 90th, 120th, 240th, 480th, and 600th minute. 
The serum insulin concentration (25µL) was 
measured using Bovine Insulin ELISA Kit. 
 
Statistical Analysis  
The differences of each treatment group 
were statistically analyzed with p<0.05 indicating 
significantly different. 
 
RESULTS AND DISCUSSION 
Development of SNEDDS templates                                                                                                                                         
The component screened for SNEDDS 
templates shows that Miglyol 812N: Tween 80: 
propylene glycol produced the mixtures fulfilling 
the designed criteria. Oleic acid and Span 85 
tend to form less transparent emulsion than 
Miglyol 812N. Mygliol 812 is medium chain 
triglyceride with the HLB value 15.36 
(Kawakami et al., 2002), while the HLB of 
Span 85 is 1.8 and HLB of  oleic acid is 1.0. It 
was reported that lipid with higher polarity is 
easier to form nano-emulsion (Hong et al., 
2006). Oil that has long hydrocarbon chain 
like oleic acid and Span 85 (C18) is difficult to 
form nano-emulsion; Miglyol 812N has such 
medium-long hydrocarbon chain that is 
emulsified easily (Anton and Vandamme, 
2009; Sadurní et al., 2005). Span 85 is a sorbitan 
trioleate, a long hydrocarbon chain, resulting 
in higher viscosity (200-300mpas) than 
Miglyol 812 has (27-33mpas) and oleic acid 
(25.6mpas); Span 85 has less spontaneous nano-
emulsifying and tends to from bigger-sized 
droplets.   
Tween 80 is able to form nano-emulsion 
with Miglyol 812 due to its higher HLB                   
value than of Cremophor EL 40; although              
HLB of Tween 80 is lower than of Tween 20,            
it can form better nano-emulsion than Tween 20 
(Chinwong et al., 2012; Macedo et al., 2006). 
 
Phase Diagram of SNEDDS Formulation 
Pseudoternary phase diagram was 
constructed to estimate the concentration in 
which SNEDDS templates can form 
nanoemulsion when added to water. The 
diagram consists of Miglyol 812N: Tween 80: 
propylene glycol (Figure 1). Red squares showed 
the nanoemulsion. 
 
Optimization of SNEDDS template with 
D-optimal 
Response of  % transmittance  
The % transmittance is one of SNEDDS 
characteristics that needs to be evaluated for its 
use to predict the size of emulsion droplets 
(Nasr et al., 2016). The equation for % 
transmittance using D-optimal Design (pseudo 




Remarks: Y1= √ transmittance; A= Miglyol 
812N composition; B= Surfactant (Tween 80) 
composition; C= Co-surfactant (propylene 
glycol) composition 
 
Based on the equation 1, oil reduced the 
% transmittance due to the improving amount 
of oil composition leading to the increased 
droplet size. It results in the decreased value of 
% transmittance (Desmukh and Kulkarni, 2014). 
In contrast, surfactants increase the value of % 
transmittance as they will be absorbed on the oil 
surface so fast that the oil changes into small-
sized droplets in continuous phase. Co-
surfactants support surfactants to reduce the 
surface tension into negative value and to 
modulate the drop size to nanometer by 
decreasing the interfacial bending stress and 
increasing the flexibility of an interfacial film 
(Nasr et al., 2016). Consequently, due to the 
synergic function, the increased amount of co-
surfactants results in the increased value of % 
transmittance.     
The oil-surfactant interaction has the 
biggest influence on % transmittance for the 
viscosity of oil-surfactant combination lower 
than of surfactant; it results in easier penetration 
of water in the nano-emulsion formation 
process (Ittiqo et al., 2016). 
 
Response of emulsification time 
Emulsification time is essential parameter 
in evaluating the efficiency of self nanoemulsion 
formation (Basalious et al., 2010; Costa et al., 2012). 
Lina winarti 




Figure 1. Pseudoternary phase diagram of SNEDDS 
template consist of Miglyol 812N:Tween 
80:Propylene glycol 
 





Figure 3. Amount of insulin transported across rat gut in vitro for 5h (average±sd) (a) insulin 




Figure 4. Profile of serum insulin concentration (Average±SEM, n=4) 
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The obtained equation of D-optimal Design 
(pseudo components) for response of 
emulsification time is as follow: 
 
Y2 = -0.029*A+0.036*B+0.15*C…………...(2) 
 
Remarks: Y2= 1/Emulsification time; A= Miglyol 
812N composition; B= Surfactant (Tween 80) 
composition; C= Co-surfactant (propylene 
glycol) 
Oil increase the emulsification time 
while both surfactant and co-surfactant 
decreases the emulsification time. Oil prolong 
the emulsification time due to different phase           
of oil and water that results in high surface            
tension prohibiting the water penetration in 
forming nano-emulsion spontaneously (Ruan 
et al., 2010).  
The optimization result shows the 
optimal ratio of Miglyol 812: Tween 80: 
propylene glycol is 10:65:25 (%w/w) with the 
desirability of 0.97. Figure 2 shows mixed 
overlay plots resulted by two responses.   
 
Verification of optimal formula 
The verification result showed no 
significant difference between the prediction 
value and observation value of Y1 and Y2             
with p>0.05 therefore that the prediction value 
experimentally fits with the observation value. 
 
Particle size and zeta potential  
The analysis result of particle size 
indicated that the droplet size of insulin nano-
emulsion is 12.0±1.7nm with narrow 
distribution size (polydispersity index = 0.243) 
and the zeta potential is +0.16mV.  
 
Visual observation of emulsification time 
Emulsification time of SNEDDS insulin 
occurs fast in three media, with emulsification 
time <60s, it belongs to grade A for less than 
one-minute emulsification time, and it has 
transparent or clear bluish appearance (Kaur et 
al., 2003). 
 
The % transmittance  
The % transmittance of SNEDDS  
insulin (>90%) indicates transparency formula 
or ability to form nano-emulsion in the used 
media. 
 
Diffusion test with ussing chamber  
Validation process to determines the level 
of insulin transported during diffusion study has 
been successfully carried out according to ICH 
Guideline Q2 (R1). Validation parameters 
include selectivity, linearity, LOD, LOQ, 
accuracy, and precision. Microbradford assay 
used in this study was selective, linear, accurate 
and precise. LOD and LOQ were obtained 
0.49μg/mL and 1.64μg/mL. The result of 
diffusion test with Ussing Chamber shows that 
the amount of transported insulin of SNEDDS 
preparation (32.45±2.03%) is significantly 
different (p=0.001) from non-SNEDDS insulin 
(10.44±5.04%) (Figure 3). The test result reveals 
that SNEDDS significantly influences the 
increase of flux and amount of in vitro 
transported insulin.  
 
Analysis of blood insulin level 
The method used to determine insulin 
levels in serum is Sandwich ELISA. Color 
intensity after the addition of TMB substrate (3, 
3', 5, 5'-tetramethylbenzidine) and stop solution 
measured using ELISA reader at the wavelength 
of 450 nm. Before use, ELISA kit was verified 
to know its linearity, accuracy, precision, and 
suitability with the internal quality controls. The 
verification results show that the standard curve 
is linear (R2 = 0.9998), accurate, precise, and in 
accordance with internal controls. 










Insulin non SNEDDS 200IU/Kg BB  0.52±0.51 15-60 27.34±10.00 0.004±0.003 
Insulin SNEDDS  43.39IU/Kg BB  0.82±0.19 45-60 85.86±16.10 0.062±0.024 
Insulin SNEDDS 108.47IU/Kg BB  0.77±0.17 240 293.23±42.76 0.084±0.027 
Insulin SNEDDS 216.94 IU/Kg BB  1.31±0.19 240 506.75±32.75 0.073±0.008 
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Protein activity depent on the intergrity of 
three dimensional structure. ELISA results show 
that SNEEDS are able to preserve biological 
activity of entrapped Insulin. After oral 
administration, SNEDDS formulation can 
increase in AUC, C max, and an F value of 
insulin (Figure 4). These caused by some factors 
including lymphatic transport, high surfactant 
content, and paracellular transport of tight 
junction (Georgakopoulos et al., 1992). The lipid 
given orally will be digested and absorbed in 
intestinal lymphatic. SNEDDS insulin forms 
nano-sized droplet system that will experience 
intestinal uptake through lymphoid follicles and 
Peyer’s patches GALT and be transported to 
spleen either directly or through macrophage 
phagocytosis effect (Reddy and Murthy, 2002). 
Insulin also transported to intestinal lymphatic 
due to its big-sized molecule and resistance to 
portal circulation absorption (Reddy and 
Murthy, 2002).  
Insulin absorption can be reached using 
enhancer (Muranishi, 1990) and lipid based vehicles 
(Porter and Charman, 2001). Long chain lipid 
will tend to be transported to spleen rather than 
to portal circulation. The oil used in SNEDDS 
system is Miglyol 812N, medium chain 
triglycerides that will be transported to intestinal 
lymphatic due to its combination with Tween 80 
consisting of oleic acid, long chain fat (C18). 
Tween 80 is an enhancer that increases the 
permeability of cell membrane. Tween 80 also 
has reversible effects in opening tight junction 
through interaction with polar parts of lipid 
bilayers (Selvam et al., 2013).  
The fastest Cmax reached by Insulin 
SNEDDS 1mL than Insulin SNEDDS 2.5 mL 
adn 5mL (Figure 4). These can be seen from 
Insulin SNEDDS given orally as much as 2.5 mL 
and 5mL reached Cmax after 240 minutes while 
Insulin SNEDDS 1mL reached Cmax after 45-
60min. These caused by delayed gastric 
emptying time (Cooke, 1975) and the slow 
dispersing process of SNEDDS into 
nanoemulsion in limited gastric media (Porter 
and Charman, 2001; Pouton, 2000). Fat has a 
long residence time in the stomach (Cooke, 
1975) which delayed gastric emptying time 
leading to delayed absorption. 
Compared with non-SNEDDS insulin, 
the SNEDDS insulin is absorbed more. This 
occurs as non-SNEDDS insulin is unstable to 
pH changes of gastrointestinal tract leading to 
unpredictable speed of insulin absorption. 
Subcutaneous insulin was used as positive 
control of blood insulin level. Cmax of this 
insulin is reached fast, in 15min, with 
4.21±0.57ng/mL of level. The Cmax of 
SNEDDS insulin of the highest dosage remains 
smaller than of subcutaneous insulin; this occurs 
due to bigger insulin hindrance to enter blood 
through oral route. The protein given 
subcutaneously will move slowly from tissues to 
capillary, and it generally reach the bloodstream 
through lymphatic vessels; the protein given 
orally must be resistant to the extreme pH 
environment and protease that can destroy 
protein, and it must be able to penetrate the 
intestinal epithelial membrane to enter the 
bloodstream. 
The result of Pharmacokinetic test reveals 
that insulin is better given in SNEDDS 
preparation than in non-SNEDDS preparation; 
this explains that it is highly possible to enhance 




The resulted design of SNEDDS 
templates reveals that the optimal SNEDDS 
template after being loaded with insulin provides 
nano-emulsion characteristic resulting in bigger 
amount of in vitro diffused and in vivo absorbed 
insulin than of non-SNEDDS insulin. This 
enables the designed SNEDDS formula to be 
used in per-oral insulin delivery. 
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